Another red alert for American science | Science www.science.org/doi/10.1126/...

8th Annual Ovarian Cancer Midwest Focus (OCMF) Conference, November 2-3, Rochester, MN Registration:https://www.ocmfconference.com/registration Abstract submission:https://docs.google.com/forms/d/e/1FAIpQLSfddMLDh4-C4ZaN6YK6ZgSLgNp8G5662vd8-oWy9e6pNua1Rw/viewform

Spatially Defined Cellular Niches Forged by Tumor-Intrinsic MHCII Redefine Immune Competence in Ovarian Cancer aacrjournals.org/cancerdiscov...

local.newsbreak.com/tampa-bay-ti... "John Cleveland, a Moffitt executive vice president, will take over Flores’s position as associate center director. Her role as division chief will be handled by Kenneth Wright, Moffitt’s associate center director of research education and training."

Moffitt executive resigns leadership role after investigation of her research www.tampabay.com/news/health/...

The Pershing Square Foundation Announces Its 2026 Lotus Award Recipients - www.businesswire.com/news/home/20...

The Pershing Square Foundation Announces Its 2026 Lotus Award Recipients — Pershing Square Philanthropies pershingsquarephilanthropies.org

Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy ir.anixa.com/press-releas...

Happy Birthday to Santiago Ramón y Cajal - the "father of modern neuroscience."

Single-cell spatial atlas of high-grade serous ovarian cancer uncovers MHC class II as a key predictor of spatial tumor ecosystems and clinical outcomes aacrjournals.org/cancerdiscov...

Sobering piece about the devastating consequences of conspiracy theories-driven vaccine hesitation: Measles Took My Daughter. This Is What I Want Everyone to Know. www.nytimes.com/2026/04/21/o...

www.nature.com/articles/s41... Should researchers avoid translational research in animals in favor of human models? We argue that this debate should focus on how experimental systems can be combined to maximize mechanistic confidence, human relevance, and real-world decision-making value.

Advances in ovarian cancer research and treatment made over the last decade, plus current challenges, emerging technologies in prevention, early detection, and treatment, and research priorities for the years ahead in press at Nature Reviews in Cancer: rdcu.be/fdbBo

I’m a Nobel Prize-winning immigrant. I can no longer recognize this country. open.substack.com/pub/ofthebra...

The biennial RIVKIN ovarian cancer symposium will take place in Philly on October 16-18. Abstracts are accepted from April 14 to July 14

Dr. Amit Kumar, CEO of Anixa Biosciences, discusses on new CAR T cell technologies to treat ovarian cancer FSH-directed CER T cells) and a vaccine against breast cancer www.youtube.com/watch?v=96uS...

A new study from Ron Buckanovich and colleagues using a human stroma-patient-derived xenograft tumor model demonstrates the impact of human tumor stroma on recruitment of TAMs and tumor immune exclusion, which alters the response to immunotherapy. rdcu.be/fa3So

The 16th Biennial Rivkin Ovarian Cancer Research Symposium will take place on October 16-18, 2026 at the Sheraton Philadelphia Downtown in Philadelphia, PA. ocrahope.org/research/riv...

Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation ir.anixa.com/press-releas...

Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization ir.anixa.com/press-releas...

Beautiful study by Sungjune Kim and Imene Hamaidi at Mayo on how SIRT2-driven LCK acetylation elevates the threshold of TCR activation, which can be targeted with inhibitors and genetic approaches in real world tumor-reactive TILs. True immunology: rdcu.be/e1iSA

Great story from Carlos Ontiveros and Tyler Curiel on the role opf PD-L2 in anti-tumor immunity in old subjects with melanoma. PD-L1 and PD-1 blockade are often equated but biologically it is not the same and they may have different clinical applications. rdcu.be/eQWiw

Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization: ir.anixa.com/press-releas...

The promise of TIL therapy for glioblastoma. Inspiring perspective from Mustafa Kharaw's team on their ongoing work to make immunotherapy effective against one of the most devastating human cancers: www.sciencedirect.com/science/arti...

Anixa Biosciences, Inc. (ANIX), which is testing CER T cells redirected against FSHR with FSH in patients with relapsed, chemoresisatnt ovarian cancer, will participate in the upcoming Water Tower Research Fireside Chat Series (November 11, 2025, at 11:00am PT) us06web.zoom.us/webinar/regi...

Leukocyte-intrinsic ER stress responses contribute to chemotherapy-induced peripheral neuropathy | Science Translational Medicine www.science.org/doi/10.1126/...

Medicine Nobel for researchers who characterized the immunobiology of regulatory T cells (previously "suppressor T cells"): www.science.org/content/arti...

working group report from the 2024 National Cancer Institute / Gynecologic Cancer Steering Committee endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer in the immunotherapy era url: academic.oup.com/jnci/article...

Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology: ir.anixa.com/press-releas...

Immune memory shapes ovarian cancer recurrence: Comment on the article of Ghisoni and Dangaj in Cancer Cell www.cell.com/cancer-cell/...

Dr. Robert Wenham, principal investigator for Anixa's ongoing ovarian cancer CAR-T therapy Phase 1 clinical trial, will be presenting at the 13th Annual Ovarcoming Cancer Conference, being held September 18 – 19, 2025, at the Briar Club in Houston, Texas. ir.anixa.com/press-releas...

This new study from Dangaj& Ghisoni in Cancer Cell analyzed 131 matching primary/relapsed ovarian cancers, to show that the immune landscape of the original tumor is re-established in the recurrent lesion, which depends on HRD status and pre-existing TIL:myeloid niches. www.cell.com/cancer-cell/...

Federal government freezes $108 million in NIH funding to Duke. Apparently for racial discrimination...against white Anglos in the Deep South...this sounds like a Tarantino movie... www.dukechronicle.com/article/2025...

In this new study, Aaron Ring and colleagues demonstrate the importance of antibody responses on the effectiveness of patients with cancer treated with ICI. As for treatment naive tumors, these are autoandibodies thsat in most cases do not cause autoimmunity: rdcu.be/exGyT

Improving lung cancer tumor infiltrating lymphocytes (TILs) manufacturing - Cytotherapy www.isct-cytotherapy.org/article/S146...

NIH announces end to funding for animal-only studies. This is potentially catastrophic. www.drugdiscoverytrends.com/nih-announce...

Zelig Eshhar, leading cancer researcher and immunologist, and the father of CAR T cells, dies at 84: www.timesofisrael.com/zelig-eshhar...

Great article from Tao wang in Nature Cancer: The abundance of tumor antigen-targeting antibodies is predictive of ICI response. Plus a new computational method to predict binding between antibodies and antigens that can be scaled to high-throughput sequencing data www.nature.com/articles/s43...

Building Better Immunotherapy: Using a method spearheaded by led by José Ramón Conejo-Garcia, MD, PhD, and Scott Antonia, MD, PhD (pictured here), immune cells are being engineered to find and attack cancer tumors. 🔗: medschool.duke.edu/stories/buil... #AcademicSky #MedSky #Immunobiology

Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial. No dose-limiting toxicities were observed in the third cohort. The trial is enrolling women with recurrent ovarian cancer who have progressed after two prior therapies. ir.anixa.com/press-releas...

Hear from OCRP leaders in this video series on how the Ovarian Cancer Academy supports researchers in making ovarian cancer the focus of their scientific careers and accelerating progress in the field: www.youtube.com/watch?v=rC2G... www.youtube.com/watch?v=ogO4... www.youtube.com/watch?v=DwWV...

Dr. Roger Li receives the Young Investigator Award of the Society of Urologic Oncology. I cannot imagine a more deserved prize. Congratulations, Roger! suonet.org/awards/young...

Anixa Biosciences Outlines Significant Progress and Key Milestones in Shareholder Letter#United_States#Anixa_Biosciences#San_Jose#CAR-T_therapy#Breast_Cancer_Vaccine

Excited to help show biology of TIL cell therapy resistance in lung cancer! Important findings in real world samples: >Missing neoantigens at progression >Failure of persistence of antigen-specific clones >HLA LOH www.nature.com/articles/s43...

New Global Ovarian Cancer Research Consortium Joins Forces with Microsoft’s AI for Good Lab to Launch First-Of-Its-Kind $1M Global Grant to Improve Survival Rates ocrahope.org/news/new-glo...

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology. The treatment is so far safe in all patients and effective in a subset of patients with recurrent ovarian cancer. Trial ongoing with more results coming soon. ir.anixa.com/press-releas...

What Is Actually the Point of Treating the N.I.H. Like This? www.nytimes.com/2025/04/11/o...

A working group report from the 2024 NCI/GCSC endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer in the immunotherapy era: academic.oup.com/jnci/advance...

To recap, Trump officials have suspended funds to: 1. Columbia ($400 million) 2. Brown ($510 million) 3. UPenn ($175 million) 4. Harvard ($9 billion) 5. Cornell ($1 billion) Perhaps we need to form a coalition or an alliance to band together. Maybe a League of some kind?

Of HIFs and hERVs: Neoantigen generation in kidney cancer: Cancer Cell www.cell.com/cancer-cell/...